Jayson Parker

Associate Professor, Teaching Stream
Master of Biotechnology/Biology

Dr. Jayson Parker is a Lecturer in medical biotechnology in the Department of Biology at the University of Toronto Mississauga. He lectures in the Master of Biotechnology Program, Faculty of Law and the Institute of Biomaterials and Biomedical Engineering. His main research interests include: biomarkers & clinical trial risk, machine learning, biotechnology patents and medical device regulation.

Dr. Parker is currently a medical/scientific advisor to the hedge fund Burlington Capital Inc, which has $25 million in assets under management and the Canadian Innovation Centre. He is also a board member for Life Sciences Ontario.  Most recently, he was a medical liaison for Schering Plough’s biologic infliximab (Remicade) and for Novo Nordisk’s biologic rfVIIa (Novoseven/Niastase). He has been a “buy side” stock analyst covering the life sciences for Investor’s Group and the Director of Medical Science Equities at AIC limited (now Portland), both prominent mutual fund companies.

His research experience includes brain imaging of Alzheimer’s disease (Sunnybrook Hospital), animal models of alcohol abuse (Addiction Research Foundation) and animal models of schizophrenia (University of Toronto). His Doctoral work was on brain trauma (sensory map plasticity) and his Master’s research on cocaine addiction (reward pathways). During his MBA he focused on competitive intelligence issues in biotechnology.


  • Rubinger D, Hollmann S, Ernst, S, Arundine, M, Serdetchnaia V and J.L. Parker.  Clinical Trial Failure Risk in Metastatic Melanoma: Biomarkers Show Promise.  Biomarkers in Medicine (in press). Impact Factor 3.2

  • Aiyere, E. Silverberg, J., Ali, S., and J.L. Parker.  Clinical trial risk in type 2 diabetes:  importance of patient history (submitted).  Journal of Pharmacy and Pharmaceutical Sciences

  • Falconi A, Lopes G and J.L. Parker (2014).  Biomarker and Receptor Targeted therapies reduce Clinical Trial Risk in Non-Small Cell Lung Cancer.  Journal of Thoracic Oncology, 9(2):163-169.  Impact Factor 4.55

  • Tenuta A, Klotz and J.L. Parker (2014) Clinical Trial Risk in Castration Resistant Prostate Cancer: Immunotherapies Show Promise.  British Journal of Urology International, May;113(5b):E82-9. doi: 10.1111/bju.12309. Epub 2013   Dec 2.; Impact Factor 3.05

  • Reid, G., T Bin Yamee and J.L. Parker (2013) Impact of Biomarkers on Clinical Trial Risk. Pharmacogenomics 14 (13): 1645-1658. Impact Factor 3.86

  • A. Chit, J. Parker, S. A. Halperin, M. Papadimitropoulos, M. Krahn, P. Grootendorst. (2013). Towards More Specific and Transparent Research and Development Costs: The Case of Seasonal Influenza Vaccines.  Vaccine. 2013 Jul 3. pii: S0264-410X(13)00847-5. doi: 10.1016/j.vaccine.2013.06.055. [Epub ahead of print].  Impact Factor 3.77

  • Parker JL, Lushina N, Bal PS, Petrella T, Dent R and Lopes G. Impact of Biomarkers on Clinical Trial Risk in Breast Cancer (2012). Breast Cancer Research Treatment, Nov; 136(1): 179-185. Impact Factor 4.47

  • Jayasundara, K., E. Keystone and J.L. Parker (2012).  Clinical trial risk in rheumatoid arthritis:  patients who fail to respond to conventional therapies.  Journal Rheumatology 2012 Nov; 39(11): 2066-2070. Impact Factor 3.26

  • B. Osborne, R. Kaul and J. L. Parker (2011).  Drug development risk in HIV-1 clinical trials: the effect of drug class.  Journal of Pharmaceutical and Health Services Research, 2: 211-216. 

  • Parker, J.L. Z. Zhang and R. Buckstein (2011).  Clinical trial risk in non-Hodgkin’s lymphoma:  endpoint and target selection.  Journal of Pharmacy and Pharmaceutical Sciences, 14(2): 227-235.  Impact Factor 2.20

  • Parker, J.L. and J. Clare-Kohler (2010).  The success rate of new drug development in clinical trials:  Crohn’s disease.  Journal of Pharmacy and Pharmaceutical Sciences, 13(2): 191-197.  Impact Factor 2.20


Current Courses
Patent Law for the Life Sciences (LAW524H1/BTC1840H), Creating Life Science Products (BTC1850H) and Introductory Medical Biotechnology (BIO375H)